Associate Director, Digital Editorial @OncLive
Cranbury, NJ
Joined December 2014
- Tweets1.8K
- Following390
- Followers521
- Likes58
Isatuximab Approved in Europe for Relapsed/Refractory Myeloma onclive.com/web-exclusives/i… #mmsm
3
Olaparib Approaches EU Approval for Frontline Maintenance in Pancreatic Cancer onclive.com/web-exclusives/o…
Palbociclib Falls Short in Phase 3 Early Breast Cancer Trial onclive.com/web-exclusives/p… #bcsm
EU Panel Backs Entrectinib for NTRK + Tumors and ROS1 + NSCLC onclive.com/web-exclusives/e… #lcsm
Alpelisib Nears EU Approval for PIK3CA+ Breast Cancer onclive.com/web-exclusives/a… #bcsm
FDA Approves Ramucirumab Plus Erlotinib for Frontline EGFR + NSCLC onclive.com/web-exclusives/f… #ASCO20 #lcsm
1
FDA Approves Atezolizumab Plus Bevacizumab for Frontline Liver Cancer onclive.com/web-exclusives/f… #ASCO20
FDA Approves Atezolizumab Plus Bevacizumab for Frontline HCC onclive.com/web-exclusives/f… via @onclive
3
Alpelisib Impresses in PI3KCA + Breast Cancer After Progression on CDK Inhibition onclive.com/conference-cover… #bcsm #ASCO20
NCCN Adds Rucaparib to Prostate Cancer Guidelines onclive.com/web-exclusives/n… #pcsm
FDA Grants Onvansertib Fast Track Designation in KRAS + mCRC onclive.com/web-exclusives/f…
FDA Waives ODAC Review of Margetuximab in HER2+ Breast Cancer onclive.com/web-exclusives/f… #bcsm
IASLC Survey Illustrates Current Barriers to Molecular Testing in Lung Cancer onclive.com/web-exclusives/i… #lcsm
Rucaparib Prostate Cancer Approval Sets Stage for Further Research onclive.com/web-exclusives/r… #pcsm
Immunotherapy Revolutionizes Melanoma Treatment Paradigm onclive.com/web-exclusives/i… #melsm @YaleCancer @SmilowCancer
Selinexor sNDA Submitted to FDA for Earlier Use in Multiple Myeloma onclive.com/web-exclusives/s… #mmsm
FDA Approves Multiple Companion Diagnostics for Olaparib in HRR+ mCRPC onclive.com/web-exclusives/f… #pcsm
Dr. Agarwal on the FDA Approval of Olaparib in HRR -Mutant mCRPC onclive.com/onclive-tv/dr-ag… #pcsm